Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.49 |
| ▸ | POLB | P06746 | 2/20 | 0.49 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.48 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.48 |
| ▸ | TP53 | P04637 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.46 |
| ▸ | SCD | O00767 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 3/20 | 0.45 |
| ▸ | LMNA | P02545 | 3/20 | 0.44 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.44 |
| ▸ | THRB | P10828 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5935437 | 0.90 | GPR119 (0.49) | GPR119POLBHCRTR1HCRTR2TP53 | |
| SCHEMBL3089588 | 0.86 | MEN1 (0.52) | GPR119POLBTP53MEN1KMT2A | |
| SCHEMBL2846468 | 0.83 | KDM4E (0.55) | POLBTP53MEN1KMT2AMAPT | |
| SCHEMBL25933 | 0.83 | POLB (0.58) | GPR119POLBMEN1KMT2AHDAC4 | |
| SCHEMBL2819482 | 0.82 | NR1H2 (0.46) | HCRTR1HCRTR2TP53SCDEPHX2 | |
| SCHEMBL30691922 | 0.81 | P2RX7 (0.57) | GPR119POLBTP53MEN1KMT2A | |
| SCHEMBL3201936 | 0.81 | HSD11B1 (0.50) | GPR119TP53MEN1KMT2AMAPT | |
| SCHEMBL34465971 | 0.81 | HSD11B1 (0.50) | GPR119TP53MEN1KMT2AMAPT | |
| SCHEMBL2821695 | 0.80 | HCRTR1 (0.50) | HCRTR1HCRTR2SCD | |
| SCHEMBL3529473 | 0.80 | POLB (0.55) | GPR119POLBTP53MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1827438-B2 | PIPERAZIN DERIVATIVES FOR INHIBITING HUMAN STEAROYL-COA-DESATURASE | XENON PHARMACEUTICALS INC (CA) | 2014-12-10 | — | — | EP | disclosed |
| US-20120004213-A1 | NOVEL PIPERAZINE DERIVATIVES AS INHIBITORS OF STEAROYL-CoA DESATURASE | FOREST LABORATORIES HOLDINGS LIMITED (BM) | 2012-01-05 | — | — | US | disclosed |
| US-20120004213-A1 | NOVEL PIPERAZINE DERIVATIVES AS INHIBITORS OF STEAROYL-CoA DESATURASE | FOREST LABORATORIES HOLDINGS LIMITED (BM) | 2012-01-05 | — | — | US | disclosed |
| US-20120004213-A1 | NOVEL PIPERAZINE DERIVATIVES AS INHIBITORS OF STEAROYL-CoA DESATURASE | FOREST LABORATORIES HOLDINGS LIMITED (BM) | 2012-01-05 | — | — | US | disclosed |
| US-8039463-B2 | Piperazine derivatives as inhibitors of stearoyl-CoA desaturase | FOREST LABORATORIES HOLDINGS LIMITED (BM) | 2011-10-18 | — | — | US | disclosed |
| US-8039463-B2 | Piperazine derivatives as inhibitors of stearoyl-CoA desaturase | FOREST LABORATORIES HOLDINGS LIMITED (BM) | 2011-10-18 | — | — | US | disclosed |
| US-8039463-B2 | Piperazine derivatives as inhibitors of stearoyl-CoA desaturase | FOREST LABORATORIES HOLDINGS LIMITED (BM) | 2011-10-18 | — | — | US | disclosed |
| EP-2316457-A1 | Pyridine derivatives for inhibiting human stearoyl-coa-desaturase | Xenon Pharmaceuticals Inc. (CA) | 2011-05-04 | — | — | EP | disclosed |
| CN-102036666-A | Novel piperazine derivatives as inhibitors of stearoyl-coA desaturase | FOREST LAB HOLDINGS LTD | 2011-04-27 | — | — | CN | disclosed |
| EP-2307023-A1 | NOVEL PIPERAZINE DERIVATIVES AS INHIBITORS OF STEAROYL-COA DESATURASE | Forest Laboratories Holdings Limited (BM) | 2011-04-13 | — | — | EP | disclosed |
| WO-2009117659-A1 | NOVEL PIPERAZINE DERIVATIVES AS INHIBITORS OF STEAROYL-COA DESATURASE | FOREST LABORATORIES HOLDINGS LIMITED (BM) | 2009-09-24 | — | — | WO | disclosed |
| US-20090239848-A1 | NOVEL PIPERAZINE DERIVATIVES AS INHIBITORS OF STEAROYL-CoA DESATURASE | FOREST LABORATORIES HOLDINGS LIMITED (BM) | 2009-09-24 | — | — | US | disclosed |
| US-20090239848-A1 | NOVEL PIPERAZINE DERIVATIVES AS INHIBITORS OF STEAROYL-CoA DESATURASE | FOREST LABORATORIES HOLDINGS LIMITED (BM) | 2009-09-24 | — | — | US | disclosed |
| EP-1996550-A2 | CARBOXYAMINE COMPOUNDS AND THEIR USE IN THE TREATMENT OF HDAC DEPENDENT DISEASES | Novartis AG (CH) | 2008-12-03 | — | — | EP | disclosed |
| US-20080255149-A1 | Carboxyamine Compounds and Methods of Use Thereof | NOVARTIS AG | 2008-10-16 | — | — | US | disclosed |
| CN-101282932-A | Carboxyamine compounds and their use in the treatment of HDAC dependent diseases | NOVARTIS AG (CH) | 2008-10-08 | — | — | CN | disclosed |
| US-20080167321-A1 | Pyridine Derivatives For Inhibiting Human Stearoyl-Coa-Desaturase | XENON PHARMACEUTICALS INC. (CA) | 2008-07-10 | — | — | US | disclosed |
| EP-1827438-A2 | PYRIDINE DERIVATIVES FOR INHIBITING HUMAN STEAROYL-COA-DESATURASE | XENON PHARMACEUTICALS INC. (CA) | 2007-09-05 | — | — | EP | disclosed |
| WO-2007038459-A2 | CARBOXYAMINE COMPOUNDS AND THEIR USE IN THE TREATMENT OF HDAC DEPENDENT DISEASES | NOVARTIS AG (CH) | 2007-04-05 | — | — | WO | disclosed |
| WO-2006034446-A2 | PYRIDINE DERIVATIVES FOR INHIBITING HUMAN STEAROYL-COA-DESATURASE | XENON PHARMACEUTICALS INC. (CA) | 2006-03-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090239848-A1 | NOVEL PIPERAZINE DERIVATIVES AS INHIBITORS OF STEAROYL-CoA DESATURASE | SCD, SCD5, FADS2 | GPR119 700/4885POLB 1958/4885HCRTR1 3143/4885 |
| US-20080255149-A1 | Carboxyamine Compounds and Methods of Use Thereof | HNMT, HDAC5, HDAC4 | GPR119 437/4885POLB 2307/4885HCRTR1 343/4885 |
| US-20080167321-A1 | Pyridine Derivatives For Inhibiting Human Stearoyl-Coa-Desaturase | SCD, SCD5, FADS2 | GPR119 136/4885POLB 3108/4885HCRTR1 3081/4885 |
| US-20120004213-A1 | NOVEL PIPERAZINE DERIVATIVES AS INHIBITORS OF STEAROYL-CoA DESATURASE | SCD, SCD5, FADS2 | GPR119 700/4885POLB 1958/4885HCRTR1 3143/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.